World Health Organization (WHO)

Concerns over marketing drugs to doctors emerged after the thalidomide tragedy of the 1950s and 60s, which was an example where promotional pressure overrode patient safety. As a result, in 1968, the WHO adopted WHA21.41, recommending truthful advertising and the inclusion of safety information about the drug. It was revised in 1988 as WHA41.17 -  the "Ethical Criteria for Medicinal Drug Promotion". Today, enforcement remains weak globally, as seen in studies from Nigeria and India that show many promotional materials lack standard information. A key complication is that some practitioners in developing countries rely on these materials as a primary information source due to limited access to unbiased journals. Some countries oppose regulation - defending pharmaceutical marketing as a legitimate form of commercial speech and driver of innovation. Delegates should consider how the international community can address misleading or incomplete promotion while respecting different national contexts, economic interests, and information needs.